biote (BTMD) Competitors $4.21 +0.02 (+0.48%) As of 07/3/2025 03:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BTMD vs. SYRE, MLYS, AVDL, PHVS, NRIX, ARDX, ORIC, PRAX, ZYME, and LENZShould you be buying biote stock or one of its competitors? The main competitors of biote include Spyre Therapeutics (SYRE), Mineralys Therapeutics (MLYS), Avadel Pharmaceuticals (AVDL), Pharvaris (PHVS), Nurix Therapeutics (NRIX), Ardelyx (ARDX), Oric Pharmaceuticals (ORIC), Praxis Precision Medicines (PRAX), Zymeworks (ZYME), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. biote vs. Its Competitors Spyre Therapeutics Mineralys Therapeutics Avadel Pharmaceuticals Pharvaris Nurix Therapeutics Ardelyx Oric Pharmaceuticals Praxis Precision Medicines Zymeworks LENZ Therapeutics biote (NASDAQ:BTMD) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation. Does the media favor BTMD or SYRE? In the previous week, Spyre Therapeutics had 1 more articles in the media than biote. MarketBeat recorded 2 mentions for Spyre Therapeutics and 1 mentions for biote. biote's average media sentiment score of 0.67 beat Spyre Therapeutics' score of 0.00 indicating that biote is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BTMD or SYRE more profitable? biote has a net margin of 10.93% compared to Spyre Therapeutics' net margin of 0.00%. biote's return on equity of -19.44% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets biote10.93% -19.44% 20.12% Spyre Therapeutics N/A -77.46%-41.06% Which has better valuation & earnings, BTMD or SYRE? biote has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$197.19M1.17$3.16M$0.616.90Spyre Therapeutics$890K1,072.85-$208.02M-$3.77-4.20 Which has more risk & volatility, BTMD or SYRE? biote has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. Do analysts recommend BTMD or SYRE? biote currently has a consensus target price of $8.00, indicating a potential upside of 90.02%. Spyre Therapeutics has a consensus target price of $53.40, indicating a potential upside of 237.12%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Do insiders & institutionals believe in BTMD or SYRE? 21.7% of biote shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 24.0% of biote shares are owned by insiders. Comparatively, 15.4% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Summarybiote beats Spyre Therapeutics on 9 of the 17 factors compared between the two stocks. Get biote News Delivered to You Automatically Sign up to receive the latest news and ratings for BTMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BTMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTMD vs. The Competition Export to ExcelMetricbioteMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.88M$10.52B$5.53B$9.04BDividend YieldN/A2.07%5.24%4.01%P/E Ratio6.9017.0327.6320.25Price / Sales1.1729.54417.36118.17Price / Cash5.5122.9936.8958.07Price / Book-1.513.668.035.67Net Income$3.16M$235.40M$3.18B$249.21M7 Day Performance0.24%2.15%2.91%3.28%1 Month Performance14.71%3.38%3.72%5.55%1 Year Performance-43.03%-10.18%35.14%21.08% biote Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTMDbiote2.68 of 5 stars$4.21+0.5%$8.00+90.0%-43.1%$230.88M$197.19M6.90194News CoverageSYRESpyre Therapeutics1.581 of 5 stars$14.97-1.6%$53.40+256.7%-38.5%$917.39M$890K-3.9773News CoverageMLYSMineralys Therapeutics2.1724 of 5 stars$13.53-1.3%$32.25+138.4%+19.5%$893.55MN/A-3.6328AVDLAvadel Pharmaceuticals2.4395 of 5 stars$8.85-3.8%$18.17+105.3%-38.6%$890M$169.12M-32.7870PHVSPharvaris1.5715 of 5 stars$17.60+3.5%$36.20+105.7%+10.4%$888.93MN/A-5.8530Positive NewsGap UpNRIXNurix Therapeutics1.5204 of 5 stars$11.39-2.1%$30.18+164.9%-34.4%$887.38M$54.55M-4.07300Trending NewsUpcoming EarningsAnalyst RevisionARDXArdelyx4.4421 of 5 stars$3.92+6.2%$10.89+177.8%-19.3%$882.85M$333.61M-17.8290ORICOric Pharmaceuticals4.161 of 5 stars$10.15-1.6%$19.17+88.8%+43.2%$878.66MN/A-5.4380PRAXPraxis Precision Medicines3.1669 of 5 stars$42.05-2.2%$109.90+161.4%+18.2%$875.87M$8.55M-3.92110ZYMEZymeworks1.9953 of 5 stars$12.55+0.6%$21.00+67.3%+53.0%$873.19M$93.38M-8.37460Analyst ForecastLENZLENZ Therapeutics1.3352 of 5 stars$29.31-2.9%$46.60+59.0%+84.2%$849.45MN/A-16.56110 Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Mineralys Therapeutics Alternatives Avadel Pharmaceuticals Alternatives Pharvaris Alternatives Nurix Therapeutics Alternatives Ardelyx Alternatives Oric Pharmaceuticals Alternatives Praxis Precision Medicines Alternatives Zymeworks Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTMD) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding biote Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share biote With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
